Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]

Jamie D. Weinand; Joshua D. Safer

doi:10.1016/j.jcte.2024.100334

Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]

Research output: Contribution to journal › Comment/debate

Abstract

In volume 2 of JCTE, page 57, in the first paragraph, the word androgen was inadvertently replaced with the word estrogen on 2 occasions. The sentence should read “In Kuroda et al. (2008), no breast carcinoma was found among FTM individuals (n = 56) who had been on androgen for an average of 11 months, while one breast carcinoma was found in among those FTM individuals (n = 130) who were not on androgen”. The authors apologise for the inconvenience caused.

Original language	English
Article number	100334
Journal	Journal of Clinical and Translational Endocrinology
Volume	35
DOIs	https://doi.org/10.1016/j.jcte.2024.100334
State	Published - Mar 2024
Externally published	Yes

Access to Document

10.1016/j.jcte.2024.100334

Fingerprint

Dive into the research topics of 'Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]'. Together they form a unique fingerprint.

Cite this

Weinand, J. D., & Safer, J. D. (2024). Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]. Journal of Clinical and Translational Endocrinology, 35, Article 100334. https://doi.org/10.1016/j.jcte.2024.100334

@article{432c49e3b1c94c2d9605ca55aea71aaf,

title = "Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]",

abstract = "In volume 2 of JCTE, page 57, in the first paragraph, the word androgen was inadvertently replaced with the word estrogen on 2 occasions. The sentence should read “In Kuroda et al. (2008), no breast carcinoma was found among FTM individuals (n = 56) who had been on androgen for an average of 11 months, while one breast carcinoma was found in among those FTM individuals (n = 130) who were not on androgen”. The authors apologise for the inconvenience caused.",

author = "Weinand, {Jamie D.} and Safer, {Joshua D.}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s)",

year = "2024",

month = mar,

doi = "10.1016/j.jcte.2024.100334",

language = "English",

volume = "35",

journal = "Journal of Clinical and Translational Endocrinology",

issn = "2214-6237",

publisher = "Elsevier BV",

}

Weinand, JD & Safer, JD 2024, 'Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]', Journal of Clinical and Translational Endocrinology, vol. 35, 100334. https://doi.org/10.1016/j.jcte.2024.100334

Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]. / Weinand, Jamie D.; Safer, Joshua D.
In: Journal of Clinical and Translational Endocrinology, Vol. 35, 100334, 03.2024.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum to “Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals” [J. JCTE 2 (2015) 55–60, (S2214623715000496), (10.1016/j.jcte.2015.02.003)]

AU - Weinand, Jamie D.

AU - Safer, Joshua D.

PY - 2024/3

Y1 - 2024/3

N2 - In volume 2 of JCTE, page 57, in the first paragraph, the word androgen was inadvertently replaced with the word estrogen on 2 occasions. The sentence should read “In Kuroda et al. (2008), no breast carcinoma was found among FTM individuals (n = 56) who had been on androgen for an average of 11 months, while one breast carcinoma was found in among those FTM individuals (n = 130) who were not on androgen”. The authors apologise for the inconvenience caused.

AB - In volume 2 of JCTE, page 57, in the first paragraph, the word androgen was inadvertently replaced with the word estrogen on 2 occasions. The sentence should read “In Kuroda et al. (2008), no breast carcinoma was found among FTM individuals (n = 56) who had been on androgen for an average of 11 months, while one breast carcinoma was found in among those FTM individuals (n = 130) who were not on androgen”. The authors apologise for the inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85188465007&partnerID=8YFLogxK

U2 - 10.1016/j.jcte.2024.100334

DO - 10.1016/j.jcte.2024.100334

M3 - Comment/debate

AN - SCOPUS:85188465007

SN - 2214-6237

VL - 35

JO - Journal of Clinical and Translational Endocrinology

JF - Journal of Clinical and Translational Endocrinology

M1 - 100334

ER -